CN101947229A - Medicinal composition for treating rhinitis - Google Patents
Medicinal composition for treating rhinitis Download PDFInfo
- Publication number
- CN101947229A CN101947229A CN2010105093697A CN201010509369A CN101947229A CN 101947229 A CN101947229 A CN 101947229A CN 2010105093697 A CN2010105093697 A CN 2010105093697A CN 201010509369 A CN201010509369 A CN 201010509369A CN 101947229 A CN101947229 A CN 101947229A
- Authority
- CN
- China
- Prior art keywords
- rhinitis
- pharmaceutical composition
- ribavirin
- nasal
- sodium phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicinal composition, which comprises pharmaceutically effective dose of tolazoline hydrochloride, gentamycin sulfate, ribavirin, dexamethasone sodium phosphate, chlorphenamine maleate and a pharmaceutical carrier. The medicinal composition can be used for treating various acute or chronic rhinitis, sinusitis, purulent rhinitis, rhinitis sicca, atrophic rhinitis, allergic rhinitis and the like.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of rhinitis, relate in particular to the pharmaceutical composition that symptoms such as the nasal obstruction that causes for various acute and chronic rhinitis, sinusitis, purulent rhinitis, rhinitis sicca, atrophic rhinitis, allergic rhinitis, watery nasal discharge, dryness in the nasal cavity, ozena, headache, dizziness have good efficacy.
Background technology
Acute and chronic rhinitis, sinusitis, atrophic rhinitis, allergic rhinitis, rhinitis sicca etc. are common multiple disease clinically, mainly contain symptoms such as nasal obstruction, watery nasal discharge, dryness in the nasal cavity, ozena, headache, cause very big painful and uncomfortable to the patient.These diseases are usually relevant with the stimulation of harmful dust, gas.In recent years, along with industrial development and atmospheric pollution aggravation, the sickness rate of these diseases is ascendant trend year by year.At present, the medicine for the treatment of these diseases clinically has ephedrine normal saline solution, Duramist Plus etc.These drug effects are relatively slow, often need to treat 5-7 talent produce effects, and side effect has xeromycteria etc., and causes medicamentous rhinitis easily.
Therefore, the medicine of symptoms such as the nasal obstruction that causes for the various acute and chronic rhinitis of effective treatment, sinusitis, purulent rhinitis, rhinitis sicca, atrophic rhinitis, allergic rhinitis, watery nasal discharge, dryness in the nasal cavity, ozena, headache, dizziness exists tangible demand.
Summary of the invention
The purpose of this invention is to provide a kind of pharmaceutical composition for the treatment of diseases such as acute and chronic rhinitis, sinusitis, purulent rhinitis, rhinitis sicca, atrophic rhinitis, allergic rhinitis, the characteristics of this pharmaceutical composition are all effective for symptoms such as the nasal obstruction that is caused by various acute and chronic rhinitis, sinusitis, purulent rhinitis, rhinitis sicca, atrophic rhinitis, allergic rhinitis, watery nasal discharge, dryness in the nasal cavity, ozena, headache, dizzinesses, treatment time is short, particularly eliminate fully for symptom after nasal obstruction watery nasal discharge, the nasal obstruction snoring medication once, effective percentage and cure rate are very high.
Pharmaceutical composition of the present invention comprises Benzazoline Hydrochloride, gentamycin sulfate, ribavirin, dexamethasone sodium phosphate, chlorphenamine maleate and the pharmaceutical carrier of pharmacy effective dose.Wherein, Tolazoline, gentamycin, dexamethasone, chlorphenamine can use with the form of other pharmaceutical salts, and these other pharmaceutical salts also are within the scope of the invention.
Described pharmaceutical carrier for example is any in the organic solvents such as normal saline, pure water, various medicinal aqueous solution, ethanol, also can be their two or more mixture.
The dosage form of pharmaceutical composition of the present invention is preferably nasal spray or nasal drop.
The specific embodiment
In pharmaceutical composition of the present invention, Benzazoline Hydrochloride is a kind of alpha-2-adrenoceptor blocker, can make nose vasodilation, alleviates nose vasospasm.Gentamycin sulfate is a kind of aminoglycosides broad ectrum antibiotic, has antibacterial and bactericidal action to multiple gram negative bacteria and gram-positive bacterium, and the nose when can be used for rhinitis infects.Ribavirin is a kind of antiviral drugs, and is many with viral infection when acute rhinitis or chronic rhinitis acute attack, can resist viral infection with ribavirin.Dexamethasone sodium phosphate is a steroidal antiinflammatory drugs, can alleviate the symptom such as nasal obstruction, watery nasal discharge of acute and chronic rhinitis.Chlorphenamine maleate has the effect of histamine H1-receptor on the stronger competitiveness blocking-up allergy target cell, plays anti-allergic effects by the antagonism to the H1 receptor, also has the effect of anti-M cholinoceptor in addition, alleviates the watery nasal discharge symptom.Described in following examples, the present invention is by combining said medicine, and symptoms such as the nasal obstruction that causes for various acute and chronic rhinitis, sinusitis, purulent rhinitis, rhinitis sicca, atrophic rhinitis, allergic rhinitis, watery nasal discharge, dryness in the nasal cavity, ozena, headache, dizziness have obtained unexpected significant curative effect.
Benzazoline Hydrochloride of the present invention, gentamycin sulfate, ribavirin, dexamethasone sodium phosphate, chlorphenamine maleate can adopt the raw material of industry, also can adopt commercially available preparation, for example can adopt Benzazoline Hydrochloride nasal drop, gentamicin injection liquid, ribavirin injection, dexamethasone sodium phosphate injection, maleate chlorpheniramine injection, compositions of the present invention can be mixed these preparations and be joined and obtain.
In a preferred embodiment, pharmaceutical composition of the present invention for example comprises the active component of following amount in the normal saline at the 10ml pharmaceutical carrier:
0.1-20mg Benzazoline Hydrochloride,
The 1-200mg gentamycin sulfate,
The 1-100mg ribavirin,
0.05-20mg dexamethasone sodium phosphate,
0.1-50mg chlorphenamine maleate.
In a preferred embodiment, pharmaceutical composition of the present invention for example comprises the active component of following amount in the normal saline at the 10ml pharmaceutical carrier:
The 1-10mg Benzazoline Hydrochloride,
The 20-80mg gentamycin sulfate,
The 30-60mg ribavirin,
0.2-5mg dexamethasone sodium phosphate,
The 1-10mg chlorphenamine maleate.
In an also preferred embodiment, pharmaceutical composition of the present invention for example comprises the active component of following amount in the normal saline at the 10ml pharmaceutical carrier:
The 4-6mg Benzazoline Hydrochloride,
The 40-50mg gentamycin sulfate,
The 40-50mg ribavirin,
0.4-1mg dexamethasone sodium phosphate,
The 1-5mg chlorphenamine maleate.
By pharmaceutical carrier such as normal saline are mixed with above-mentioned active component, compositions of the present invention can be made suitable dosage form, for example nasal spray, nasal drop etc.
During use, nasal spray directly can be sprayed to nasal cavity, 2-3 time on the one, spray under the 2-4 at every turn.Perhaps nasal drop directly is added drop-wise in the nasal cavity, every day 1-3 time, one time 2-3 drips, and gets final product in general treatment 3-5 days.
Embodiment
The present invention is described by the following examples.
Embodiment 1
Commercially available Benzazoline Hydrochloride nasal drop, gentamicin injection liquid, ribavirin injection, dexamethasone sodium phosphate injection, maleate chlorpheniramine injection are mixed, make nasal spray, make the active component that contains following amount in every 10ml liquid:
The 5mg Benzazoline Hydrochloride,
The 50mg gentamycin sulfate,
The 50mg ribavirin,
The 5mg dexamethasone sodium phosphate,
The 2mg chlorphenamine maleate.
Embodiment 2
Commercially available Benzazoline Hydrochloride nasal drop, gentamicin injection liquid, ribavirin injection, dexamethasone sodium phosphate injection, maleate chlorpheniramine injection are mixed, make nasal drop, make the active component that contains following amount in every 10ml liquid:
The 1mg Benzazoline Hydrochloride,
The 20mg gentamycin sulfate,
The 50mg ribavirin,
The 1mg dexamethasone sodium phosphate,
The 1mg chlorphenamine maleate.
Embodiment 3
Commercially available Benzazoline Hydrochloride nasal drop, gentamicin injection liquid, ribavirin injection, dexamethasone sodium phosphate injection, maleate chlorpheniramine injection are mixed, make nasal spray, make the active component that contains following amount in every 10ml liquid:
The 10mg Benzazoline Hydrochloride,
The 50mg gentamycin sulfate,
The 50mg ribavirin,
The 2mg dexamethasone sodium phosphate,
The 10mg chlorphenamine maleate.
Embodiment 4
In the 10ml normal saline, add following material, make nasal spray:
The 5mg Benzazoline Hydrochloride,
The 50mg gentamycin sulfate,
The 50mg ribavirin,
The 5mg dexamethasone sodium phosphate,
The 2mg chlorphenamine maleate.
Drug test
Use is carried out clinical trial according to the nasal spray of the prescription of the embodiment of the invention 1 in the department of otorhinolaryngology outpatient service, treat 320 routine various acute and chronic rhinitis patients altogether with medicine of the present invention, patient age is 18-68 year, course of disease a couple of days to the several years is not waited, and with nasal spray of the present invention every day twice, pushes under the shower nozzle 2-4 at every turn, general treatment 3-5 days, as a result, cure 317 examples, cure rate is more than 99%.Through clinical observation, find medicine instant effect of the present invention, particularly once promptly eliminate for nasal obstruction watery nasal discharge, nasal obstruction snoring medication.Than Duramist Plus commonly used clinically at present, effect is more excellent.
Claims (6)
1. pharmaceutical composition that is used for the treatment of rhinitis, it comprises Benzazoline Hydrochloride, gentamycin sulfate, ribavirin, dexamethasone sodium phosphate, chlorphenamine maleate and the pharmaceutical carrier of pharmacy effective dose.
2. pharmaceutical composition according to claim 1 wherein, comprises the active component of following amount in the 10ml pharmaceutical carrier:
0.1-20mg Benzazoline Hydrochloride,
The 1-200mg gentamycin sulfate,
The 1-100mg ribavirin,
0.05-20mg dexamethasone sodium phosphate,
0.1-50mg chlorphenamine maleate.
3. pharmaceutical composition according to claim 1 wherein, comprises the active component of following amount in the 10ml pharmaceutical carrier:
The 1-10mg Benzazoline Hydrochloride,
The 20-80mg gentamycin sulfate,
The 30-60mg ribavirin,
0.2-5mg dexamethasone sodium phosphate,
The 1-10mg chlorphenamine maleate.
4. pharmaceutical composition according to claim 1 wherein comprises the active component of following amount in the 10ml pharmaceutical carrier:
The 4-6mg Benzazoline Hydrochloride,
The 40-50mg gentamycin sulfate,
The 40-50mg ribavirin,
0.4-1mg dexamethasone sodium phosphate,
The 1-5mg chlorphenamine maleate.
5. according to each described pharmaceutical composition of claim 1-4, wherein said pharmaceutical composition is a nasal spray.
6. according to each described pharmaceutical composition of claim 1-4, wherein said pharmaceutical composition is a nasal drop.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105093697A CN101947229A (en) | 2010-10-18 | 2010-10-18 | Medicinal composition for treating rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105093697A CN101947229A (en) | 2010-10-18 | 2010-10-18 | Medicinal composition for treating rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101947229A true CN101947229A (en) | 2011-01-19 |
Family
ID=43450937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105093697A Pending CN101947229A (en) | 2010-10-18 | 2010-10-18 | Medicinal composition for treating rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101947229A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109568333A (en) * | 2018-12-26 | 2019-04-05 | 江西润泽药业有限公司 | A kind of nasal drops and preparation method thereof for treating rhinitis |
| CN111671887A (en) * | 2020-07-27 | 2020-09-18 | 李秀华 | Chinese and western medicine formula for treating chronic rhinitis with comprehensive special effect and treatment method |
-
2010
- 2010-10-18 CN CN2010105093697A patent/CN101947229A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109568333A (en) * | 2018-12-26 | 2019-04-05 | 江西润泽药业有限公司 | A kind of nasal drops and preparation method thereof for treating rhinitis |
| CN111671887A (en) * | 2020-07-27 | 2020-09-18 | 李秀华 | Chinese and western medicine formula for treating chronic rhinitis with comprehensive special effect and treatment method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saunders et al. | Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients | |
| BR112015029491A2 (en) | imidazopyrrolidinone derivatives and their use in the treatment of disease | |
| TW201016209A (en) | Intranasal compositions, dosage forms and methods of treatments | |
| RU2010140682A (en) | METHOD FOR TREATING PATIENTS FROM INFECTION, PHARMACEUTICAL COMPOSITION (OPTIONS) AND MEDICINE | |
| ES2390226T3 (en) | Treatment of infectious diseases | |
| WO2004105731A8 (en) | Nasal formulations including a topical decongestant and a topical corticosteroid and their use in treatment of obstructive sleep apnea | |
| JP2013516482A5 (en) | ||
| SI2889033T1 (en) | Treatment of negative symptoms of schizophrenia with (R)-7-chloro-N-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| HRP20140592T1 (en) | Improved medicinal compositions comprising buprenorphine and naltrexone | |
| RU2008152341A (en) | APPLICATION OF ALLOPURINOL FOR TREATMENT OF PALM-SOIL ERYTHRODESESTHESIA | |
| JP2013519653A (en) | Treatment of loss of touch with saxitoxin derivatives | |
| US20160166505A1 (en) | Methods And Compositions For Treatment Of Respiratory Tract Infections | |
| KR20110014199A (en) | Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis | |
| WO2011074015A3 (en) | Composition of pharmaceutical product to treat sexual dysfunction | |
| HRP20192189T1 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| JP2016505050A5 (en) | ||
| WO2006131833A3 (en) | New hybrid oligomers. their preparation process and pharmaceutical compositions containing them | |
| CN101947229A (en) | Medicinal composition for treating rhinitis | |
| MXPA06008240A (en) | Treatment methods. | |
| CN101703775A (en) | Medicinal composition for treating canker sore and local infection of body surface and reducing inflammation, product and application thereof | |
| KR20170117077A (en) | An external preparation containing a pyridonecarboxylic acid-based derivative | |
| JP2015524460A5 (en) | ||
| WO2020036478A3 (en) | Synergistic pharmaceutical composition comprising aceclofenac and betamethasone for the treatment of pain in localised forms of rheumatic illnesses | |
| Musmade et al. | Fusidic acid–Topical antimicrobial in the management of Staphylococcus aureus | |
| EP3103438B1 (en) | Topical nasal compositions containing xyloglucans for use as decongestans |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110119 |